Oral GHRP-2 given long-term to GH-deficient adults significantly increased appetite and body weight alongside GH/IGF-1 elevation, confirming orexigenic effects are a persistent feature of chronic GH secretagogue therapy.
Persistent appetiteThe appetite-increasing effect of GHRP-2 didn't fade with chronic use — it's a sustained feature of GH secretagogue therapy, not a transient side effect
What the researchers found
Chronic oral GHRP-2 in GH-deficient adults produced persistent increases in appetite and body weight alongside GH/IGF-1 elevation, confirming sustained orexigenic effects of long-term GH secretagogue therapy.
Why it matters
The persistent appetite increase from GH secretagogues is both a feature (for cachexia treatment) and a bug (for patients wanting GH benefits without weight gain). This defines the clinical trade-off.
How the study worked
Clinical trial of oral GHRP-2 in GH-deficient adults. Appetite (subjective assessment), body weight, GH, and IGF-1 measured over the treatment course.
What this study cannot tell us
Open-label clinical trial. Specific appetite and weight quantification limited in abstract. The body weight gain composition (fat vs lean) not detailed.
How to read the evidence
Moderate evidence from a clinical trial in the target population demonstrating persistent orexigenic effects alongside hormonal endpoints.
When this study was published
Published in 2003. The appetite side effect of GH secretagogues is now well-established and factored into clinical decision-making.
The bigger picture
Every GH secretagogue prescriber must manage the appetite-weight trade-off. For wasting patients, appetite increase is therapeutic. For others, dietary counseling or combination therapy may be needed.
Questions still open
- Can the appetite effect be managed with dietary guidance?
- Would combining GHRP-2 with GLP-1 agonists counteract appetite increase?
- Is the weight gain primarily fat or lean mass?
Common questions
Will GH peptides make me hungry?
Does the hunger go away over time?
Read the original research
Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children.
Journal of pediatric endocrinology & metabolism : JPEM, 16(7), 981-5
Citation
Mericq, Verónica; Cassorla, Fernando; Bowers, Cyril Y; Avila, Alejandra; Gonen, Boas; Merriam, George R. (2003). Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children.. Journal of pediatric endocrinology & metabolism : JPEM, 16(7), 981-5.